Physician profile
Muhammad Munir
NPI 1164495321
$3,769.50
in general payments reported to CMS, 2019-2025
29 companies · $617 in 2025
The $617 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $636 · 2021: $783 · 2022: $595 · 2023: $547 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $617 · Food and Beverage: $547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $616.60 |
| Food and Beverage | $546.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $730.70 | 2019-2023 | Brilinta, Lokelma |
| Biotronik INC. | $616.60 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $514.12 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $395.51 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $232.17 | 2019-2021 | |
| Amgen INC. | $203.28 | 2019-2021 | |
| Novo Nordisk INC | $136.82 | 2019-2023 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $115.48 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $114.00 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $96.29 | 2021 | |
| Glaxosmithkline, LLC. | $94.54 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $68.14 | 2023 | Inpefa |
| Esperion Therapeutics, INC. | $63.70 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $59.58 | 2020-2021 | |
| Janssen Biotech, INC. | $57.89 | 2022-2023 | Tremfya |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $41.29 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $34.51 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.33 | 2020-2021 | |
| Grt US Holding, INC. | $18.97 | 2022 | |
| Merck Sharp & Dohme LLC | $18.62 | 2023 | Verquvo, Belsomra |
| Ibsa Pharma INC. | $18.29 | 2020 | |
| Amneal Pharmaceuticals LLC | $17.31 | 2022 | |
| Pfizer INC. | $16.59 | 2023 | |
| Abbvie INC. | $14.56 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $13.57 | 2022 | |
| Lundbeck LLC | $13.20 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.88 | 2020 | |
| Amarin Pharma, INC. | $12.80 | 2020 | |
| Avanir Pharmaceuticals, INC. | $11.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Munir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.